Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response

References

• Steinhoff M, Cevikbas F, Yeh I, et al. Evaluation and management of a patient with chronic pruritus. J Allergy Clin Immunol. 2012;130:1015–1016.e7.
   PubMed Web of Science ®Google Scholar
• Kowalski EH, Kneiber D, Valdebran M, et al. Treatment-resistant prurigo nodularis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:163–172.
   PubMed Web of Science ®Google Scholar
• Szöllősi AG, McDonald I, Szabó IL, et al. TLR3 in chronic human itch: a keratinocyte-associated mechanism of peripheral itch sensitization. J Invest Dermatol. 2019;139:2393–2396.e6.
   PubMed Web of Science ®Google Scholar
• Werfel T, Wollenberg A, Pumnea T, et al. [New aspects in systemic treatment of atopic dermatitis]. Hautarzt. 2018;69:217–224.
   PubMed Web of Science ®Google Scholar
• Zheng T, Oh MH, Oh SY, et al. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol. 2009;129:742–751.
   PubMed Web of Science ®Google Scholar
• Steinhoff MS, von Mentzer B, Geppetti P, et al. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev. 2014;94:265–301.
   PubMed Web of Science ®Google Scholar
• Steinhoff M, Bienenstock J, Schmelz M, et al. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol. 2006;126:1705–1718.
   PubMed Web of Science ®Google Scholar
• Liang Y, Jacobi HH, Reimert CM, et al. CGRP-immunoreactive nerves in prurigo nodularis-an exploration of neurogenic inflammation. J Cutan Pathol. 2000;27:359–366.
   PubMed Web of Science ®Google Scholar
• Johansson O, Liang Y, Marcusson JA, et al. Eosinophil cationic protein- and eosinophil-derived neurotoxin/eosinophil protein X-immunoreactive eosinophils in prurigo nodularis. Arch Dermatol Res. 2000;292:371–378.
   PubMed Web of Science ®Google Scholar
• Johansson O, Liang Y, Emtestam L. Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin – an exploration of the cause of neurohyperplasia. Arch Dermatol Res. 2002;293:614–619.
   PubMed Web of Science ®Google Scholar
• Haas S, Capellino S, Phan NQ, et al. Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis. J Dermatol Sci. 2010;58:193–197.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Hong HC, Eshtiaghi P, et al. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78:S28–S36.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335–2348.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389:2287–2303.
   PubMed Web of Science ®Google Scholar
• de Bruin-Weller M, Thaci D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE). Br J Dermatol. 2018;178:1083–1101.
   PubMed Web of Science ®Google Scholar
• Iking A, Grundmann S, Chatzigeorgakidis E, et al. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol. 2013;27:550–557.
   PubMed Web of Science ®Google Scholar
• Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity. Acta Derm Venerol. 2012;92:502–507.
   PubMed Web of Science ®Google Scholar
• Almustafa ZZ, Weller K, Autenrieth J, et al. Dupilumab in treatment of chronic prurigo: a case series and literature review. Acta Derm Venereol. 2019;99:905–906.
   PubMed Web of Science ®Google Scholar
• Rambhia PH, Levitt JO. Recalcitrant prurigo nodularis treated successfully with dupilumab. JAAD Case Rep. 2019;5:471–473.
   PubMedGoogle Scholar
• Zhai LL, Savage KT, Qiu CC, et al. Chronic pruritus responding to dupilumab – a case series. Medicines (Basel). 2019;6:72.
   Google Scholar
• Tanis R, Ferenczi K, Payette M. Dupilumab treatment for prurigo nodularis and pruritis. J Drugs Dermatol. 2019;18:940–942.
   PubMed Web of Science ®Google Scholar
• Beck KM, Yang EJ, Sekhon S, et al. Dupilumab treatment for generalized prurigo nodularis. JAMA Dermatol. 2019;155:118–120.
   PubMed Web of Science ®Google Scholar
• Holm JG, Agner T, Sand C, et al. Dupilumab for prurigo nodularis: case series and review of the literature. Dermatol Ther. 2020;33:e13222.
   PubMed Web of Science ®Google Scholar
• Mollanazar NK, Elgash M, Weaver L, et al. Reduced itch associated with dupilumab treatment in 4 patients with prurigo nodularis. JAMA Dermatol. 2019;155:121–122.
   PubMed Web of Science ®Google Scholar
• Calugareanu A, Jachiet M, Tauber M, et al.; French Group of Research and Study in Atopic Dermatitis (Groupe de Recherche sur l'Eczéma Atopique, GREAT) from the French Society of Dermatology (SFD). Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients. J Eur Acad Dermatol Venereol. 2020;34:e74–e76.
   PubMed Web of Science ®Google Scholar
• Calugareanu A, Jachiet M, Lepelletier C, et al. Dramatic improvement of generalized prurigo nodularis with dupilumab. J Eur Acad Dermatol Venereol. 2019;33:e303–e304.
   PubMed Web of Science ®Google Scholar
• Giura MT, Viola R, Fierro MT, et al. Efficacy of dupilumab in prurigo nodularis in elderly patient. Dermatol Ther. 2020;33:e13201.
   PubMed Web of Science ®Google Scholar
• Mollanazar NK, Qiu CC, Aldrich JL, et al. Use of dupilumab in patients who are HIV-positive: report of four cases. Br J Dermatol. 2019;181:1311–1312.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Scalvenzi M, et al. Effectiveness of dupilumab for the treatment of generalized prurigo nodularis phenotype of adult atopic dermatitis. Dermatitis. 2020.
   PubMed Web of Science ®Google Scholar
• Ferrucci S, Tavecchio S, Berti E, et al. Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy. J Dermatolog Treat. 2019.
   Web of Science ®Google Scholar
• Chiricozzi A, Maurelli M, Gori N, et al. Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. J Am Acad Dermatol. 2020;83:39–45.
   PubMed Web of Science ®Google Scholar
• Olesen CM, Holm JG, Nørreslet LB, et al. Treatment of atopic dermatitis with dupilumab: experience from a tertiary referral centre. J Eur Acad Dermatol Venereol. 2019;33:1562–1568.
   PubMed Web of Science ®Google Scholar
• Armario-Hita JC, Pereyra-Rodriguez J, Silvestre JF, et al. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series. Br J Dermatol. 2019;181:1072–1074.
   PubMed Web of Science ®Google Scholar
• Cevikbas F, Braz JM, Wang X, et al. Synergistic antipruritic effects of gamma aminobutyric acid A and B agonists in a mouse model of atopic dermatitis. J Allergy Clin Immunol. 2017;140:454–464.e2.
   PubMed Web of Science ®Google Scholar
• Meng J, Moriyama M, Feld M, et al. New mechanism underlying IL-31-induced atopic dermatitis. J Allergy Clin Immunol. 2018;141:1677–1689.e8.
   PubMed Web of Science ®Google Scholar
• Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N Engl J Med. 2020;382:706–716.
   PubMed Web of Science ®Google Scholar
• Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011;165:990–996.
   PubMed Web of Science ®Google Scholar
• Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171:217–228.e13.
   PubMed Web of Science ®Google Scholar
• Campion M, Smith L, Gatault S, et al. Interleukin-4 and interleukin-13 evoke scratching behaviour in mice. Exp Dermatol. 2019;28:1501–1504.
   PubMed Web of Science ®Google Scholar
• Zeidler C, Yosipovitch G, Ständer S. Prurigo nodularis and its management. Dermatol Clin. 2018;36:189–197.
   PubMed Web of Science ®Google Scholar